Blood tests for diagnosing Alzheimer's disease
Accuracy of Blood-based Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice
This study is testing if new blood tests can help doctors diagnose Alzheimer's disease more easily and accurately in everyday medical settings.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 40 Years to 100 Years |
| Sex | All |
| Sponsor | Helse Stavanger HF Government |
| Locations | 1 site (Stavanger) |
| Trial ID | NCT05187819 on ClinicalTrials.gov |
What this trial studies
This project evaluates the effectiveness of new blood-based biomarkers for diagnosing Alzheimer's disease in a general practice setting. Current diagnostic methods like cerebrospinal fluid analysis and PET scans are costly and not widely accessible, making them impractical for routine use. The study aims to determine if these blood tests can reliably differentiate Alzheimer's from other neurodegenerative disorders in a population with a lower prevalence of the disease. By simplifying the diagnostic process, the study hopes to improve patient care and support.
Who should consider this trial
Good fit: Ideal candidates are individuals suspected of having dementia by their general practitioner.
Not a fit: Patients with severe psychiatric diseases or those unable to consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a cost-effective and accessible method for diagnosing Alzheimer's disease.
How similar studies have performed: Other studies have shown promise with blood-based biomarkers for Alzheimer's, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants suspected by their GP to have possible dementia, based on history, clinical examination and/or cognitive screening Exclusion Criteria: * Lack of capacity for consent as judged by the GP. * Severe psychiatric disease, use of medication or physical disease that according to the GP may affect participation or likely contribute significantly to the observed cognitive impairment. * Patients not wanting to be referred to the memory outpatient clinic.
Where this trial is running
Stavanger
- Stavanger University Hospital — Stavanger, Norway (Recruiting)
Study contacts
- Study coordinator: Svein R Kjosavik, MD PhD
- Email: svein.kjosavik@sus.no
- Phone: +4790414252
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.